However, the growth potential of MOG-specific B cells, as assessed by expression of the KI-67 marker, shows a trend (P = 0.06) for a lower expression in MS patients that may contribute to the lower frequency of anti-MOG-BBR in MS. This evidence concerns the gene MOG and myeloid sarcoma.